Change: -2.82 %Chge: -1.83% Vol: 85,802
VRTX Chart
You need Flash Player to see the chart, please download from the link below
Related Healthcare and Pharmaceuticals Companies
| Onyx Pharmaceuticals |
37.96
|
74,374 |
| Bruker |
22.29
|
57,720 |
| Lilly Eli |
34.6
|
7,278,000 |
| Health Net |
27.72
|
40,175 |
| Bio Rad Labs |
201.715
|
16,024 |
| Biomarin Pharmaceutical |
128.96
|
51,685 |
| Aetna |
43.93
|
562,588 |
| Covance |
57.52
|
1,235,900 |
Above is a small selection of related companies to Vertex Pharmaceuticals which compete alongside VRTX within the Healthcare and Pharmaceuticals sector. To see more related companies to VRTX, view our stock market today information page.
Online News For Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) a Buy on Solid Earnings Momentum
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is classified as a member of the 345 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. VRTX has a market value of $38.8 billion which is in the top 10% of its ...
Brant Point Investment Management Lowered Beacon Roofing Supply (BECN) Stake; Vertex Pharmaceuticals (VRTX) Shorts Increased By 10.12%
Brant Point Investment Management Llc decreased Beacon Roofing Supply Inc (BECN) stake by 12.23% reported in 2017Q2 SEC filing. Brant Point Investment Management Llc sold 10,000 shares as Beacon Roofing Supply Inc (BECN)’s stock rose 6.61%. The Brant ...
CIBC upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Outperform in a report released today.
Yesterday Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded 0.02% higher at $127.16. The company’s 50-day moving average is $154.14 and its 200-day moving average is $137.63. The last stock close price is down 12.35% from the 200-day moving ...
Vertex Pharmaceuticals (NDAQ:VRTX) target price raised to $181.00, reported today by RBC Capital Markets
Vertex Pharmaceuticals (NDAQ:VRTX) had its target price raised to $181.00 by RBC Capital Markets in a report released Wednesday October 18, 2017. The new target price indicates a possible upside of 0.17% based on the company's last stock close price.
Vertex Pharmaceuticals (VRTX) and Acorda Therapeutics (ACOR) Head to Head Analysis
Vertex Pharmaceuticals has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Want To Add This Quote To Your Site?
With our stock widgets you can add a Vertex Pharmaceuticals quote to your website to keep your users up to date with the market. We have a variety of different styled widgets for VRTX to choose from. Visit here to build your stock quote widget »
